Affimed N.V. (AFMD) announced the FDA has granted RMAT designation to the combination therapy of Affimeds innate cell engager acimtamig and Artiva Biotherapeutics AlloNK or AB101 for the treatment of relapsed or refractory Hodgkin Lymphoma. The designation provides Affimed enhanced access to FDA resources including the potential for accelerated approval and priority review.
The combination is being evaluated in the LuminICE-203 multicenter, multi-cohort phase 2 trial. Earlier in the year, Affimed reported promising early efficacy data from cohorts 1 and 2 of the LuminICE-203 trial.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.